Reaching mid-stage is a defining milestone for Medtech companies—but scaling beyond it presents new operational, regulatory, and capital challenges. This CEO-led discussion explores the decisions, tradeoffs, and inflection points that shaped their growth, including how geography, talent hubs, and ecosystem support influenced their trajectory.

• What specific inflection point signaled you were no longer an “early-stage company”—and how did that change how you operated?
• Which decisions you made at Series A or B mattered most in getting to mid-stage, and which ones would you revisit?
• How did your regulatory and reimbursement strategy need to evolve once early traction turned into commercial demand?
• What role did geography play in access to talent, capital, and customers—and how has that changed as you’ve scaled?
• Looking ahead, what will most determine your next phase of growth: capital, regulatory pathways, market access, or organizational maturity?
• What advice would these CEOs give founders planning their next phase of growth?​

Moderator:
Lori Chmura, CEO, Leadership, Nyra Medical

Panelists:
Omari Bouknight, CEO, Resonant Link Medical
Kathryn Dehn, Partner, Fox Rothschild 
Ramin Mousavi, President & CEO, CathWorks
Christopher Owens, President & CEO, R3 Vascular Inc